Corbus Pharmaceuticals Holdings Inc expected to post a loss of $1.28 a share - Earnings Preview

Corbus Pharmaceuticals Holdings

02/05/2025 14:33

Corbus Pharmaceuticals Holdings Inc CRBP.OQ CRBP.O is expected to show no change in quarterly revenue when it reports  results on May 5 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Corbus Pharmaceuticals Holdings Inc is for a loss of $1.28 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 0.5% in the last three months. ​

Wall Street's median 12-month price target for Corbus Pharmaceuticals Holdings Inc is $51.00​, above​ its last closing price of $7.52. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-1.26
-1.27
-0.78
Beat
38.4
Sep. 30 2024
-0.95
-0.95
-1.15
Missed
-20.8
Jun. 30 2024
-1.16
-1.19
-0.90
Beat
24.2​
Mar. 31 2024
-1.09
-1.09
-0.83
Beat
23.9
​​Dec. 31 2023
-2.22
-2.36
-1.81
Beat
23.3
Sep. 30 2023
-2.06
-2.06
-2.05
Beat
0.5​
Jun. 30 2023
-3.10
-3.10
-2.05
Beat
33.9
Mar. 31 2023
-4.09
-4.09
-4.24
Missed
-3.7

This summary was machine generated May 2 at 13:33 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)